Arcturus Therapeutics And The Cystic Fibrosis Foundation Have Extended Their Ongoing Agreement. The Cf Foundation Agreed To Increase Its Financial Commitment To ~$25M To Advance ARCT-032 To Treat Cystic Fibrosis
Portfolio Pulse from Benzinga Newsdesk
Arcturus Therapeutics and the Cystic Fibrosis Foundation have extended their ongoing agreement, with the latter increasing its financial commitment to approximately $25M to advance ARCT-032, a treatment for Cystic Fibrosis.
September 26, 2023 | 12:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Arcturus Therapeutics' ongoing agreement with the Cystic Fibrosis Foundation has been extended, with an increased financial commitment of ~$25M to advance ARCT-032, a Cystic Fibrosis treatment.
The news of the extended agreement and increased financial commitment from the Cystic Fibrosis Foundation is positive for Arcturus Therapeutics. This could potentially accelerate the development of ARCT-032, which could lead to future revenue growth if the treatment is successful and approved. Therefore, this news is likely to have a positive impact on Arcturus Therapeutics' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100